Eli Lilly CEO David Ricks on 3-year obesity drug study: This is a profound result
0
0
20/08/24
Dans
Amérique du Nord / États-Unis
CNBC’s Angelica Peebles and Eli Lilly chairman and CEO David Ricks join 'Squawk on the Street' to discuss results of the company's 3-year obesity study, which showed its highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with prediabetes compared with a placebo.
Montre plus
0 commentaires
sort Trier par